Aragen's Preclinical Oncology Capabilities

Recent advancements in immuno-oncology (IO) have led to more effective and targeted cancer treatments, including the approval of CAR T-cell therapies for hard-to-treat cancers. While CAR T-cell therapy has shown success in hematologic malignancies, challenges remain in its application to solid tumors, such as targeted delivery, tumor penetration, and safety.

To overcome these obstacles, various animal models, including humanized models and CD34+ stem cell reconstituted models, are used for screening CAR T-cell therapeutics and bispecific antibodies. Aragen Life Sciences provides specialized in vivo pharmacology services, offering customized solutions to support the development of immune-oncology therapies from discovery to commercialization.